On February 27, 2026, SHINE Technologies, a nuclear fusion company, announced it has raised $240 million in equity funding led by NantWorks founder Dr. Patrick Soon-Shiong, with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, Oaktree Capital Management, and other existing investors. Wilson Sonsini Goodrich & Rosati advised lead investor OZ Shine LLC—a new investment company led by Dr. Soon-Shiong—on the transaction.

In connection with OZ Shine's $150 million investment, OZ Shine and SHINE have entered a strategic partnership that includes priority access arrangements for Lu-177 supply from SHINE. Lu-177-based therapies deliver targeted radiation precisely to cancer cells, and researchers are actively studying how combining that approach with immune activation could produce more durable patient outcomes.

The Wilson Sonsini team that advised OZ Shine LLC on the transaction includes:

Corporate
Marty Waters
Savir Punia
Karl Kobylecki

Corporate Finance
Charlotte Kim

Technology Transactions
Seth Flaum
Aleksandar Vitomirov

Tax
Greg Broome

Intellectual Property
Sara Patak
Ying Chen

Energy and Climate Solutions
Nicole Gambino 

Regulatory
Eva Yin
Anne Seymour
Joshua Gruenspecht

For more information, please see SHINE's news release.